Literature DB >> 18812695

Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways.

Pierpaolo Paba1, Daniela Bonifacio, Luigi Di Bonito, Domenico Ombres, Cartesio Favalli, Kari Syrjänen, Marco Ciotti.   

Abstract

OBJECTIVE: Oncogenic human papillomaviruses (HPVs) are the etiological agents of cervical cancer. Different cofactors might be needed for malignant transformation, but they still remain elusive.
METHODS: To delineate the role of Chlamydia trachomatis (CT) and herpes simplex virus type 2 (HSV2) in HPV-positive cervical intraepithelial neoplasia (CIN) lesions and cervical carcinoma a series of 149 cervical cancer and CIN biopsies were analyzed for CT and HSV2 DNA by PCR, and HPV genotyped by InnoLipa. Monitoring of aberrations in key intracellular pathways due to CT/HSV2 and HPV co-expression were analyzed with 13 biomarkers.
RESULTS: Of the 149 samples tested, 136 were HPV DNA positive; 32/136 contained also CT DNA and 29 HSV2 DNA. Detection of CT was significantly (p = 0.0001) related to multiple-type HPV infections, while HSV2 was of borderline significance (p = 0.053). Of the 13 biomarkers tested, cytoplasmic and nuclear NF-kappaB and VEGF-C were significantly increased in CT+/HPV+ lesions; p = 0.023, p = 0.045, and p = 0.020 as well as survivin, p = 0.026. Survivin was the only marker that was overexpressed also in HSV2+/HPV+ lesions, p = 0.027.
CONCLUSIONS: CT infection favors the entry and persistence of multiple HR-HPV types, which leads to viral integration, inhibition of apoptosis, overexpression of E6/E7 oncogenes and cell transformation. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812695     DOI: 10.1159/000156481

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  23 in total

1.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

2.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

3.  Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis.

Authors:  Giulia Naldini; Chiara Grisci; Manuela Chiavarini; Roberto Fabiani
Journal:  Int J Public Health       Date:  2019-06-08       Impact factor: 3.380

4.  Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.

Authors:  Lynette J Menezes; Ubin Pokharel; Staci L Sudenga; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim van der Loeff; Louvina E van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano
Journal:  Sex Transm Infect       Date:  2017-05-10       Impact factor: 3.519

Review 5.  Interplay between viruses and bacterial microbiota in cancer development.

Authors:  Dariia Vyshenska; Khiem C Lam; Natalia Shulzhenko; Andrey Morgun
Journal:  Semin Immunol       Date:  2017-06-09       Impact factor: 11.130

6.  Risk factors and communities disproportionately affected by cervical cancer in the Russian Federation: A national population-based study.

Authors:  Anastasiya Muntyanu; Vladimir Nechaev; Elena Pastukhova; James Logan; Elham Rahme; Elena Netchiporouk; Andrei Zubarev; Ivan V Litvinov
Journal:  Lancet Reg Health Eur       Date:  2022-06-30

7.  Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion.

Authors:  André Lp de Abreu; Natália Malaguti; Raquel P Souza; Nelson S Uchimura; Érika C Ferreira; Monalisa W Pereira; Maria Db Carvalho; Sandra M Pelloso; Marcelo G Bonini; Fabrícia Gimenes; Marcia El Consolaro
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

8.  Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.

Authors:  Joseph G Skeate; Tania B Porras; Andrew W Woodham; Julie K Jang; Julia R Taylor; Heike E Brand; Thomas J Kelly; Jae U Jung; Diane M Da Silva; Weiming Yuan; W Martin Kast
Journal:  J Gen Virol       Date:  2015-11-10       Impact factor: 3.891

9.  Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - a pilot study.

Authors:  Neerja Bhatla; Kriti Puri; Elizabeth Joseph; Alka Kriplani; Venkateswaran K Iyer; V Sreenivas
Journal:  Indian J Med Res       Date:  2013-03       Impact factor: 2.375

10.  Chlamydia trachomatis Frequency in a Cohort of HPV-Infected Colombian Women.

Authors:  Edith Margarita Quinónez-Calvache; Dora Inés Ríos-Chaparro; Juan David Ramírez; Sara Cecilia Soto-De León; Milena Camargo; Luisa Del Río-Ospina; Ricardo Sánchez; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.